GeneticsinMedicine(2022)24,344–363
www.journals.elsevier.com/genetics-in-medicine
ARTICLE
Implementation of fetal clinical exome sequencing:
Comparing prospective and retrospective cohorts
ARTICLE INFO ABSTRACT
Article history: Purpose:Wecomparedthe diagnosticyieldof fetalclinicalexomesequencing(fCES) inpro-
Received8 April2021 spective and retrospective cohorts of pregnancies presenting with anomalies detected using
Revised23July2021 ultrasound.Weevaluatedfactorsthatledtoahigherdiagnosticefficiency,suchasphenotypic
Accepted 22September2021 category, clinicalcharacterization,andvariantanalysisstrategy.
Availableonline30November2021 Methods: fCES was performed for 303 fetuses (183 ongoing and 120 ended pregnancies, in
which chromosomal abnormalities had been excluded) using a trio/duo-based approach and a
Keywords: multistep variantanalysisstrategy.
Fetal clinicalexomesequencing
Results:fCESidentifiedtheunderlyinggeneticcausein13%(24/183)ofprospectiveand29%
Prenatal diagnosis (35/120) of retrospective cases. In both cohorts, recessive heterozygous compound genotypes
Ultrasoundabnormalities were not rare, and trio and simplex variant analysis strategies were complementary to achieve
the highest possible diagnostic rate. Limited prenatal phenotypicinformation led to interpreta-
tionchallenges.In2prospectivecases,in-depthanalysisallowedexpansionofthespectrumof
prenatalpresentationsforgeneticsyndromesassociatedwiththeSLC17A5andCHAMP1genes.
Conclusion:fCESisdiagnosticallyefficientinfetusespresentingwithcerebral,skeletal,urinary,
or multiple anomalies. The comparison between the 2 cohorts highlights the importance of
providing detailed phenotypic information for better interpretation and prenatal reporting of
genetic variants.
©2021AmericanCollegeofMedicalGeneticsandGenomics.
PublishedbyElsevierInc.All rightsreserved.
Introduction
introduction of chromosomal microarray analysis (CMA),
Ultrasounddetectionoffetalabnormalities,whichoccursin the diagnostic rate of chromosomal anomalies increased by
approximately 2% to 4% of pregnancies,1,2 is an essential 4%to7%.3-5However,thesearchforageneticdiagnosisin
part of routine obstetrical care. When fetal structural the remaining cases was costly and time-consuming before
anomalies are suspected, invasive procedures (ie, amnio- the introduction of next-generation sequencing (NGS). The
centesis, chorionic villus sampling [CVS]) are offered for encouraging results of exome sequencing (ES) in pediatric
prenatal genetic diagnosis. Historically, karyotype testing patients6-10 raised interest for its application in a prenatal
was the first-line method to investigate chromosomal setting. Since 2014, several studies comprising small and
anomalies, providing a diagnosis in approximately 30% of selected cohorts of aborted fetuses reported high diagnostic
fetuses with abnormal ultrasound findings.3 With the yields(intherangeof50%-80%).11-15Recently,2largeand
CatherineDonner,LauraTecco,andDominiqueThomascontributedequally.
JulieDe´sirandMarcAbramowiczcontributedequally.
*CorrespondenceandrequestsformaterialsshouldbeaddressedtoMartinaMarangoniandIsabelleMigeotte,CenterofHumanGenetics,HoˆpitalErasme,
Universite´ LibredeBruxelles,RoutedeLennik808,Anderlecht,Brussels1070,Belgium.E-mailaddress:Martina.Marangoni@erasme.ulb.ac.be;Isabelle.
Migeotte@erasme.ulb.ac.be
Afulllistofauthorsandaffiliationsappearsattheendofthepaper.
doi:https://doi.org/10.1016/j.gim.2021.09.016
1098-3600/©2021AmericanCollegeofMedicalGeneticsandGenomics.PublishedbyElsevierInc.Allrightsreserved.
M. Marangoni et al. 345
unselected prospective cohorts were reported with a lower for which no parental DNA was available (ie, only trio/duo
diagnosticrate(8%-10%).16,17AstheuseofESincreasesin analysis was performed). Families were informed about the
prenatal care, medical professionals (eg, referring physi- technicalaspectsandthelimitationsofthestudybyaclinical
cians, laboratory geneticists, genetic counselors) are faced geneticist or a trained gynecologist, and written informed
with complex technical and ethical challenges that must be consentwasobtained.Theparentscouldoptinoroutofthe
addressed collectively.18 returnofincidentalfindings.Thisstudywasapprovedbythe
Hereinwereportfetalclinicalexomesequencing(fCES) ethicalcommitteeoftheHoˆpitalErasme,Brussels,Belgium,
in a series of 303 pregnancies displaying abnormal ultra- under the reference P2016/236.
sound findings (with no selection of the type of fetal
anomalies) and normal quantitative fluorescent–polymerase Clinical data collection
chain reaction and CMA results, including 183 pregnancies
for which the diagnosis was obtained during the pregnancy
In the retrospective study, information about fetal pheno-
and hence contributed to the clinical decision process.
types was collected from imaging data and postmortem
Importantly,theretrospectiveandprospectiveanalyseswere
examinations when available and used for genotype–phe-
carried out by the same center and in the same time frame,
notype correlation during fCES analysis. In the prospective
allowingdirectcomparisonofthediagnosticyieldsbetween
study, fCES interpretation was based on imaging data
the 2 cohorts. In particular, we discuss the effect of the
availableatthetimeoftheanalysis.Retrospectively,clinical
availability of detailed phenotypic information for the
data were reviewed in all cases, and phenotypes were an-
establishmentofgeneticdiagnosesthroughfetalNGS-based
notated using Human Phenotype Ontology (HPO) (https://
analyses.In addition, our series expanded the range offetal
hpo.jax.org/app/) terms,19 allowing classification in several
phenotypes investigated by genome-wide methods because
phenotypic categories (Supplemental Table 3).
itincludedfetusespresentingwithanomaliesdetectedusing
ultrasound anomalies that have rarely been explored by
fCES
NGS (ie, intrauterine growth restriction, amniotic fluid ab-
normalities) and uncovered novel associations between
known genotypes and fetal phenotypes. Finally, our study Library preparation and sequencing
aimed to share data analysis workflow strategies and inter- In the prospective study, fetal DNA was obtained from
pretation challenges. CVS, amniotic fluid, or fetal blood that remained unused
afterroutineinvestigations.WhentheamountofDNAfrom
these samples was insufficient, DNA was extracted from
Materials and Methods cultured samples. In the retrospective study, cultured fibro-
blasts or fetal biopsies were used for DNA extraction if no
other type of sample was available. Parental blood samples
Study design and participants
were also collected for DNA extraction. In all prenatal
samples, maternal contamination and presence of the most
Patients were recruited from 14 centers (Supplemental
common aneuploidies were excluded by quantitative
Table 1) between October 2016 and June 2020, and their
fluorescent–polymerase chain reaction (Elucigene QST*R
enrollment was conducted in parallel for both cohorts.
Plus v2, Elucigene Diagnostics). CMA on a CytoSure
However, because of a long turnaround time (TAT) at the
Constitutional v3 8×60k array (Oxford Gene Technology)
beginning of the study, the cases recruited initially mostly
was performed to exclude copy number variations (CNVs).
consisted of interrupted pregnancies. The study design is
LibrarypreparationwasperformedusingKAPAHyperPrep/
summarizedinFigure1A.Fortheretrospectivestudycohort,
HyperPlusLibraryPreparationKit(RocheNimbleGenInc).
couples who had experienced a pregnancy characterized by
An in-house SeqCap EZ Choice XL Probes (Roche Nim-
fetalanomaliesforwhichthefetalsamplewasavailablewere
bleGen Inc) targeting the coding exons of genes associated
recruited. For the prospective study cohort, on detection of
fetal structural anomalies during a routine ultrasound exam- with Mendelian disorders was used (4 designs)
ination, parents who opted for invasive testing were offered (Supplemental Table 4). Libraries were sequenced on Illu-
participation. Inclusion and exclusion criteria were the same mina HiSeq 1500/NovaSeq 6000 (Illumina Inc). Bioinfor-
for both cohorts. Inclusion criteria were increased nuchal matics pipeline was run at Brussels Interuniversity
translucency (NT) (>99th percentile and/or ≥3.5 mm at 11- Genomics High Throughput core (BRIGHTcore) (http://
14 weeks ultrasound scan), amniotic fluid anomalies, or any www.brightcore.be/). The mean coverage of fetal samples
major structural fetal malformation(s). Exclusion criteria
wasbetween250×and300×,andtheparentalsampleswere
were fetuses presenting isolated soft markers (Supplemental sequenced at 150×. Reads were aligned to the reference
Table 2), known monogenic disease within the family, genome(GRCh37/hg19)usingtheBurrows-WheelerAligner
identification of an etiology (chromosomal abnormality, (version 0.7.10), and variant calling was performed using
infection) explaining the fetal phenotype, and simplex cases Genome Analysis Toolkit (version 3.3).
346 M. Marangoni et al.
Figure 1 A. Schematic representation of the study flow. B. Summary of the multistep strategy used. *Optional––performed when fetal
anomalies were specific for 1 system or were highly suggestive of defined genetic disorders. AD, autosomal dominant; AR, autosomal
recessive; CMA, chromosomal microarray analysis; fCES, fetal clinical exome sequencing; NA, not applicable; QF-PCR, quantitative
fluorescent–polymerase chainreaction; VUS,variantof unknownsignificance.
M. Marangoni et al. 347
Variant filtering American College of Medical Genetics and Genomics rec-
Variant filteringand interpretation were carried out through ommendations for reporting of secondary findings22 were
Highlander (https://sites.uclouvain.be/highlander/) accord- not followed. In particular, fetal incidental findings were
ingtoallelefrequencyandeffectonproteinandinheritance reported only if highly penetrant pathogenic/likely patho-
pattern(denovo,homozygousandcompoundheterozygous, genic variants were detected in genes known to cause
X-linked[XL]inheritanceinthecaseofmalefetuses).fCES moderateorseverechildhood-onsetdisorders.Pathogenicor
datawereanalyzedbyalaboratoryscientistincollaboration likely pathogenic variants in genes known to cause medi-
with prenatally involved clinical geneticists using the cally actionable dominant conditions (inherited cancer
collected clinical information about fetal phenotypes (as syndromes, cardiovascular, and others) were reported
described in the clinical data collection section). In partic- exclusively in the parental reports if they had consented to
ular, variant filtering included several steps (Figure 1B). the return of these results.
First, a comprehensive in silico panel of genes (up to 1273
genes) involved in congenital anomalies (developed from Variant validation
Pangalos et al13 and Fetal anomalies panel from Genomics VariantswereconfirmedbySangersequencingiftheyarose
England PanelApp [https://panelapp.genomicsengland.co.
as a de novo event in the index case or if the variant call-
uk/]) (Supplemental Table 5) was analyzed using a trio/ specific metrics (eg, read depth, allele balance, strand bias)
duo-based approach, exploring the different inheritance
and/or their genomic context (eg, presence of repeats,
patterns. Second, trio/duo analysis of the entire clinical
pseudogenic regions) were considered suboptimal.
exome (up to 4867 genes) (Supplemental Table 4) was
accomplished for all inheritancemodes. Ifthe results of the
Statistical analysis
previous analyses were negative and the fetal anomalies
were specific for 1 system or were highly suggestive of
definedgeneticdisorders, furtherin silico gene panels were The number of diagnostic variants in the 2 cohorts was
compared using a χ2 test performed using GraphPad Prism
investigated exclusively in the proband (simplex analysis)
v.7.0 (GraphPad Software).
using Genomics England PanelApp, GeneReviews (https://
www.ncbi.nlm.nih.gov/books/NBK1116/), HPO, or the
most recent literature. In selected cases (ie, only 1 likely
Results
pathogenic/pathogenicvariantdetectedingenesresponsible
for recessive disorders), single exon CNVs were detected
using Copy Number Variation Detection In NGS gene Atotalof300coupleswererecruited,and303fetalsamples
panels20 and exonic CNV data were visualized using in- (120 terminated and 183 ongoing pregnancies) were pro-
house software. This exonic CNV pipeline was run cessedforfCES(SupplementalTables6and7).FetalDNA
retrospectively. was obtained from amniocentesis (68.9%, 209/303), CVS
(14.1%, 43/303), fetal blood (6.6%, 20/303), or tissue
Variant interpretation samples (10.2%, 31/303). Male to female ratios were 0.94
Variant interpretation and classification followed interna- (89/94)and1.2(66/54)intheprospectiveandretrospective
tional guidelines (pathogenic: class V; likely pathogenic: cohorts, respectively. fCES was mostly performed in trio
class IV; variant of unknown significance (VUS): class III; (176 prospective and 116 retrospective cases), followed by
likely benign: class II; benign: class I).21 For class V, we duo (7 prospective cases) or quartet (4 retrospective cases
used stringent criteria because the analysis had to be per- belonging to 2 couples). In the prospective group preg-
formed with phenotypic information that was limited to the nancy, outcomes were available for 105 of 183 fetuses
prenatalstages(ie,fetalultrasoundand,ifavailable,nuclear (57%). Of these, the parents opted for termination in 45
magnetic resonance imaging) and, for the majority of pro- pregnancies (25%), 6 ended in miscarriages (3%), 2 ended
spective cases, absent/limited postnatal phenotypic charac- in neonatal deaths (1%), and 52 were livebirths (28%). In
terization;therefore,onlythevariantsalreadyreportedinthe contrast,intheretrospectivecohort,thepregnancyoutcome
literature as pathogenic were classified as class V. None- was known in most cases (109/120, 91%). Ninety of them
theless, highly suspicious novel variants (eg, loss-of- were terminated (82.5%), 16 ended in miscarriages (15%),
function variant in a dosage-sensitive gene) within genes and 3 ended in neonatal death (2.5%).
related to the fetal phenotype were classified as likely Among the prospective cases, warning signs were vari-
pathogenic (class IV) and reported. In addition, if further able.Somephenotypiccategoriesrepresentedasmallsample
informationwasneededforcorrectinterpretationofthedata
size(<10cases),suchasanomaliesoftheendocrinesystem
or if a potential discrepancy between the genetic findings (0.5%, 1/183), digestive tract (1.6%, 3/183), genital
and the fetal phenotype was noted, candidate variants were system (1.6%, 3/183), spine (1.6%, 3/183), face (2.2%,
discussed in a multidisciplinary team. 4/183), fluid regulation (2.2%, 4/183), musculature (2.7%,
Our ethical review board–approved informed consent 5/183),andamnioticfluidvolume(3.3%,6/183)(Figure2B).
form did not mention the possibility of opting in/out of Fetuses presenting with abnormalities in growth (5.5%,
reporting secondary variant information. Therefore, the 10/183), urinary tract (6%, 11/183), cardiovascular system
348 M. Marangoni et al.
Figure2 A.OverallfCESresultsintheprospectivecohortanddiagnosticyieldofeachanalysisstep.B.Proportionofsolvedcasesfor
eachphenotypiccategory.C.DistributionofHPOterms.D.CorrelationbetweenthepositivediagnosesandthenumberofHPOterms.fCES,
fetalclinical exomesequencing; HPO,HumanPhenotypeOntology; VUS,variantof unknownsignificance.
(7.7%, 14/183), skeleton (8.2%, 15/183), nervous system In the prospective cohort, our multistep variant analysis
(12%, 22/183), multiple organs (33.9%, 62/183), and NT process provided a genetic diagnosis in 24 of 183 cases
(10.9%, 20/183) represented larger cohorts (Figure 2B). In (13%)(Figure2A,Table1).Noneofthe7casesforwhicha
contrast, most of the retrospective cases displayed multiple duo-based analysis was performed could be solved. Most
(65.8%,79/120)andcerebralabnormalities(11.7%,14/120), diagnostic variants (18/24, 75%) were found through anal-
followedbyfetuseswithspinal(6.7%,8/120),urinary(5.8%, ysisofthecongenitalanomaliesgenepanel(Figures1Band
7/120), fluid regulation (3.3%, 4/120), facial (3.3%, 4/120), 2A). Four additional cases (4/24, 16.7%) were solved
skeletal (1.7%, 2/120), cardiovascular (0.8%, 1/120), and through analysis of the whole clinical exome (Figures 1B
digestive(0.8%,1/120)defects(Figure3B). and2A).Aspecificinsilico gene panel insimplex analysis
M. Marangoni et al. 349
Figure3 A.OverallfCESresultsintheretrospectivecohortanddiagnosticrateofeachanalysisstep.B.Proportionofsolvedcasesfor
eachphenotypiccategory.C.DistributionofHPOterms.D.CorrelationbetweenthepositivediagnosesandthenumberofHPOterms.*Only
one pathogenic variant in an autosomal recessive gene (case R56) (Supplemental Table 7). fCES, fetal clinical exome sequencing; HPO,
HumanPhenotypeOntology; NA,notapplicable;VUS, variantofunknown significance.
(ie, only filtering on the proband variants) solved 2 more variant (genes: PIK3CA, ZIC2, TSC2, NRAS, COL1A1,
cases (2/24, 8.3%) (Figure 2A). Among the positive cases, CHAMP1, ARID1B, TP63, RASA1) (Table 1). Autosomal
only1presentedarelevantfamilyhistory(ie,affectedfetus recessive(AR)disorderswerediagnosedin11cases(46%),
from previous pregnancy). When only consanguineous including 6 (54.5%) with compound heterozygous variants
couples (n = 12) were taken into account, the diagnostic and 5 (45.5%) with homozygous variants (genes: MKS1,
yield increased to 42% (5/12). In the whole prospective PKHD1,PKD1,SLC7A9,TPO,RBM8A,SLC17A5,COQ9,
cohort, autosomal dominant (AD) disorders accounted for BBS7) (Table 1). In this last subgroup, consanguinity was
46% (n = 11) of cases and all were caused by a de novo notedin4of5cases,andafounderpathogenic variant was
Table1 Overviewofthediagnosesidentifiedintheprospectivecohort
fCESInterpretation
Post-mortem Variant Strategythat
Exams/ Recurrence Classification Identifiedthe Classification
Case Phenotypic Prenatal Postnatal Overall ofthe Variant(s)and Phenotype's Pathogenic Additional Phenotype's Pregnancy
Number Category Findings Finings HPTerms Consanguinity Disorder Transcript Gene ProteinEffect(s) Contribution Inheritance Variant(s) Disorder OMIM Findings Contribution Inheritance Outcome
P3 Multiple Occipital Postaxialfoot HP:0002085; N N NM_017777.4 MKS1 c.1408-34_ VFull Recessive Insilicogene Meckel 249000 N - - TOPat12w
encephalocele, polydactyly, HP:0001539; 1408-6del homozygote panel- syndrome1
omphalocele, bilateral HP:0000113; Congenital
polycystic postaxial HP:0001830; anomalies
kidney polydactyly, HP:0006136; (design2)
dysplasia bileduct HP:0001408
proliferation
P4 Abnormality Polycystic NA HP:0000113 N N NM_138694.4 PKHD1 c.5321G>A IV,VFull Compound Insilicogene Polycystic 263200 N - - Newborn
ofthe kidney p.(Cys1774Tyr) heterozygote panel- kidney
urinary dysplasia c.8312T>C Congenital disease4,
system p.(Val2771Ala) anomalies withor
(design2) without
hepatic
disease
P6a Multiple Largefor Diaphragmatic HP:0001520; N N NM_006218.4 PIK3CA c.1030G>A VFull Denovo Insilicogene PIK3CA-Related 615108/ N - - TOPat34w
gestational eventration, HP:0000256; p.(Val344Met) panel- Overgrowth 612918/
age, hypertelorism, HP:0009110; Congenital Spectrum 602501
macrocephaly, abnormality HP:0001561; anomalies
polyhydramnios, ofthehairline, HP:0002089; (design2)
pulmonary intestinal HP:0000316;
hypoplasia duplication HP:0009553;
(smallbowel, HP:0100668
distalpart)
P7 Multiple Fetalcystichygroma NA HP:0010878; N N NM_000202.8 IDS c.1072C>A IVPartial X-linked Insilicogene Mucopolysaccharidosis 309900 N - - TOPat26w
(4.25mm), HP:0001539; p.(Pro358Thr) panel- II
omphalocele, HP:0000776; Congenital
congenital HP:0002089 anomalies
diaphragmatic (design2)
hernia,
pulmonary
hypoplasia
P26 Abnormality Oligohydramnios, NA HP:0001562; Y N NM_ PKD1 c.3820G>A IVFull Recessive ClinicalExome Polycystic 173900 N - - Fetal
ofthe polycystic HP:0000113; 001009944.3 p.(Val1274Met) homozygote kidney demise
urinary kidneydysplasia, HP:0004719 disease1c
system hyperechogenic
kidneys
P32b Abnormality Cerebellarhypoplasia,AgenesisofcorpusHP:0001321; Y N NM_007129.5 ZIC2 c.1109G>A IVFull Denovo Insilicogene Holoprosencephaly5 609637 N - - Newborn
ofthe absentseptum callosum, HP:0001331; p.(Cys370Tyr) panel-
nervous pellucidum, focal HP:0001360; Congenital
system holoprosencephaly polymicrogyria, HP:0001274; anomalies
(Middle abnormality HP:0032471; (design2)
interhemispheric ofthefalx HP:0010653;
variant) cerebri HP:0007165;
(hypoplasia), HP:0001252;
periventricular HP:0005280;
heterotopia, HP:0003196;
muscular HP:0000463
hypotonia,
depressed
nasalbridge,
shortnose,
anteverted
nares
P41 Abnormality Antenatal Cystinuria, HP:0003131; N N NM_001243036.2SLC7A9 c.1A>G IV,VFull Compound ClinicalExome Cystinuria 220100 N - - Newborn
ofthe hyperechoic ornithinuria, HP:0003532; p.(Met1?) heterozygote
digestive colon hyperlysinuria, HP:0003297; c.313G>A
system argininuria HP:0003268 p.(Gly105Arg)
(continued)
350
M.
Marangoni
et
al.
Table1 Continued
fCESInterpretation
Post-mortem Variant Strategythat
Exams/ Recurrence Classification Identifiedthe Classification
Case Phenotypic Prenatal Postnatal Overall ofthe Variant(s)and Phenotype's Pathogenic Additional Phenotype's Pregnancy
Number Category Findings Finings HPTerms Consanguinity Disorder Transcript Gene ProteinEffect(s) Contribution Inheritance Variant(s) Disorder OMIM Findings Contribution Inheritance Outcome
P83 Multiple Cardiac NA HP:0009729; N N NM_000548.5 TSC2 c.1001T>G IVFull Probablyde Insilicogene Tuberous 613254 N - - TOP
rhabdomyoma, HP:0009592; p.(Val334Gly) novo(duo panel- sclerosis-2
astrocytoma, HP:0009717 analysis) Congenital
corticaltubers anomalies
(design2)
P84 Multiple Increasednuchal NA HP:0010880; N N NM_002524.5 NRAS c.34G>A VFull Denovo Insilicogene Noonan 613224 N - - Fetal
translucency, HP:0007430; p.(Gly12Ser) panel- syndrome6 demise
generalized HP:0001762 Congenital inutero
edema,talipes anomalies at15w
equinovarus (design2)
P108 Abnormality Femoralbowing NA HP:0002980 N N NM_000088.4 COL1A1 c.1876G>A VFull Denovo Insilicogene Osteogenesis 259420/ N - - TOPat17w
ofthe (bilateral) p.(Gly626Ser) panel- imperfecta, 166220
skeletal Congenital typeIII/IV
system anomalies
(design2)
P128 Abnormality Goiter, Hearing HP:0000853; N N NM_000547.5 TPO c.209C>T IV,VFull Compound ClinicalExome Thyroid 274500 N - - Newborn
ofthe hypothyroidism impairment HP:0000821; p.(Pro70Leu) heterozygote dyshormonogenesis
endocrine HP:0000365 c.1184_1187 2A
system dupGCCG
p.(Ala397Profs
*76)
P129 Abnormality Bilateralradial NA HP:0004977; N N NM_005105.5 RBM8A c.67+32G>C IVFull Compound Genomics Thrombocytopenia- 274000 N - - Newborn
ofthe aplasia,aplasia/ HP:0006507; Microdeletion heterozygote England absentradius
skeletal hypoplasiaofthe HP:0004059 1q21.1 PanelApp: syndrome
system humerus,radial Radial
clubhand dysplasia
P131 Multiple Increased NA HP:0010880; N N NM_001164144.3CHAMP1 c.2134A>T IVFull Denovo Clinical Mental 616579 N - - TOP
nuchal HP:0000776 p.(Lys712*) Exome retardation,
translucency autosomal
(4mm),congenital dominant
diaphragmatic 40
hernia
P132 Multiple Agenesisof NA HP:0001274; N N NM_001363725.2ARID1B c.2918delT IVFull Denovo Insilico Coffin-Siris 135900 N - - Newborn
corpuscallosum, HP:0011039 p.(Met973ArgfsTer11) gene syndrome1
abnormality panel-
ofthehelix Congenital
anomalies
(design2)
P136 Multiple Hydropsfetalis, Peritoneal HP:0001789; N N NM_012434.5 SLC17A5c.308G>A IV,VFull Compound GenomicsEngland Salladisease 604369 N - - TOPat25w
hyperechogenic effusion,pleural HP:0004719; p.(Trp103*) heterozygote PanelApp:
kidneys, effusion,short HP:0002240; dupex8-9 Fetalhydrops/
hepatomegaly lowerlimbs, HP:0030995; CoNVaDING
hypertelorism, HP:0002202;
depressed HP:0006385;
nasalridge, HP:0000316;
labial HP:0000457;
hypertrophy, HP:0000065;
hypoplasia HP:0006657;
offirstribs, HP:0008142
delayed
calcaneal
ossification
(continued)
M.
Marangoni
et
al.
351
Table1 Continued
fCESInterpretation
Post-mortem Variant Strategythat
Exams/ Recurrence Classification Identifiedthe Classification
Case Phenotypic Prenatal Postnatal Overall ofthe Variant(s)and Phenotype's Pathogenic Additional Phenotype's Pregnancy
Number Category Findings Finings HPTerms Consanguinity Disorder Transcript Gene ProteinEffect(s) Contribution Inheritance Variant(s) Disorder OMIM Findings Contribution Inheritance Outcome
P146 Multiple Oligohydramnios, NA HP:0001562; Y N NM_020312.4 COQ9 c.197_198delAG IVFull Recessive Insilicogenepanel-CoenzymeQ10 614654 IL7R(NM_ IVUnknown Recessive Newborn
severe HP:0008846; p.(Gln66ArgfsTer6) homozygote Congenital deficiency, 002185.5): homozygote death
intrauterine HP:0001321; anomalies primary,5 c.83-1G>A after
growth HP:0001320; (design3) (secondary 1hoflife
retardation, HP:0001640; finding)
cerebellar HP:0010943;
hypoplasia, HP:0004719;
hypoplasia HP:0001791;
ofthe HP:0002269
corpuscallosum,
cardiomegaly,
echogenic
fetalbowel,
hyperechogenic
kidneys,
fetalascites,
abnormality
ofneuronal
migration
P158 Multiple Increasednuchal NA HP:0010880; N N NM_003722.5 TP63 c.728G>A VPartial Denovo Insilicogene Ectrodactyly, 604292 LZTR1(NM_ IIIUnknown Compound Not
translucency HP:0002202; p.(Arg243Gln) panel- ectodermal 006767.4): heterozygote available
(7mm), HP:0001789; Congenital dysplasia, c.594-3C>T
pleuraleffusion, HP:0001770 anomalies andcleftlip c.988A>G
hydropsfetalis, (design3) p.(Ser330Gly)
toesyndactyly
P167 Multiple Mildfetal NA HP:0010952; N N NM_002890.3 RASA1 c.261_262delAG VFull Denovo Insilicogene Capillary 608354 N - - TOPat23w
ventriculomegaly, HP:0001640; p.(Gly89ArgfsTer22) panel- malformation-
cardiomegaly, HP:0100659; Congenital arteriovenous
abnormality HP:3000037 anomalies malformation1
ofthecerebral (design3)
vasculature,
abnormality
ofneckblood
vessel
P170 Abnormality Urogenitalsinus Generalized HP:0100779; N N NM_176824.3 BBS7 c.1119delA IVFull Compound Insilicogene Bardet-Biedl 615984 N - - Newborn
ofthe anomaly, edema, HP:0001791; p.(Lys373AsnfsTer9) heterozygote panel- syndrome7
genital fetalascites broadneck, HP:0007430; c.712A>G Congenital
system low-setears, HP:0000475; p.(Arg238Gly) anomalies
hand HP:0000369; (design3)
polydactyly, HP:0001161;
footpolydactyly HP:0001829
Detailsareprovidedonlywhenthepatientsagreedwithpersonaldatapublication(19/24).
aCasealreadypublishedinPMID:31568861.
bCasealreadypublishedinPMID:32695376.
cUsuallyADbutprenatalcaseshavingARinheritancehavebeendescribed(PMID:31079206,22034641,23624871).
352
M.
Marangoni
et
al.
M. Marangoni et al. 353
present in the remaining case. One XL disorder was found SimilartoADdisorders,ARdiseases werediagnosedin17
(1/24, 4.2%) (gene: IDS)(Table1), and adigenicdiagnosis cases (17/35, 49%) with compound heterozygous (9/35,
was proposed in 1 case (1/24, 4.2%). Interestingly, 2 cases 26%) and homozygous variants (8/35, 23%) (genes: NEB,
involveddetectionofasinglenucleotidechangealongwith ASCC1, ASPM, GBE1, B3GALNT2, ISPD, CEP290,
a CNV (genes: RBM8A and SLC17A5) (Table 1). The PIEZO1, TUBGCP6, TNNT3, DDX11, ALG3, ETFA)
highest diagnostic yields in the prospective cohort (among (Table 2). In 5 of 8 fetuses (63%) presenting with homo-
subgroupswith≥10cases)wereobtainedforskeletal(20%, zygous variants, the parents were consanguineous, whereas
n = 3/15), multiple (19%, n = 12/62), urinary (18%, n = in most other cases the variants were hotspot variants.
2/11),andcerebralanomalies (14%, n=3/22)(Figure2B). Moreover,anXLdisorderwasdiagnosed(1/35,3%)(gene:
Three cases from our prospective series warranted further IDS)(Table2).Thegreatestproportionofdiagnosticgenetic
description(seeSupplementalCaseReportsfordetails).The variants (subgroups with ≥10 cases) were found in fetuses
discovery of a novel fetal phenotype caused by a novel presenting with multiple (34%, n = 27/79) and cerebral
variant within a known gene is illustrated by case P131 for (28.5%, n = 4/14) anomalies (Figure 3B).
which a de novo truncating variant of the CHAMP1 gene TheaveragenumberofHPOtermsusedwas5,andmost
(Supplemental Figure 2, Supplemental Case Reports), ofthe cases were described using 3 or4 terms (Figure 3C).
associated with AD mental retardation (OMIM 616579), Asseenintheprospectivecohort,thereisatrendsuggesting
was detected in a fetus presenting with increased NT and thatadetailedfetalphenotypecharacterizationenhancesthe
congenital diaphragmatic hernia. Case P136, presenting likelihood of a diagnosis (Figure 3D).
with hydrops fetalis, hyperechogenic kidneys, and hepato- VUS that may have contributed to the fetal phenotype
megaly,wassolvedbythedetectionof1pathogenicvariant were reported in 7% of prospective (12/183) and retro-
intheSLC17A5gene(Salladisease,OMIM604369)––bya spective (8/120) cases (Figures 2A and 3A, Supplemental
simplexanalysisofaninsilicopanelhydropsfetalis––along Table 8). The analysis of the gene panel for congenital
with a SLC17A5 microduplication detected after the CNV anomalies(Figure1B)allowedVUSidentificationin4of12
analysisthroughCopyNumberVariationDetectionInNGS prospective and 3 of 8 retrospective cases. In 5 of 12 pro-
gene panels (Supplemental Figure 1, Supplemental Case spective and 5 of 8 retrospective cases, VUS were detected
Reports), showing the need for multiple analysis strate- after analysis of all fCES genes. In the prospective cohort,
gies. In numerous cases, medical teams are faced with additional simplex gene panel analyses identified the 3
variantinterpretationchallenges,asincaseP178presenting remaining VUS.
with spina bifida, lemon sign, and mild fetal ven- Fetal incidental findings were reported in 2 prospective
triculomegalyforwhichcompoundheterozygousVUSwere cases (Supplemental Table 9), and 2 of the 3 variants re-
detected in the SCRIB gene (Supplemental Figure 3, ported were found after the analysis of all the fCES gene
Supplemental Case Reports), a candidate gene for neural content.Parentalincidentalfindingswerereportedin5cases
tube defects. (1 retrospective and 4 prospective cases), and they were
Most fetuses in the prospective cohort were classified mostly detected through whole clinical exome analysis
using1to3HPOterms(Figure2C),withamediannumber (Supplemental Table 10).
of2terms.Althoughthecorrelationbetweenfrequencyofa The average TAT, defined as the number of days be-
positive diagnosis and the number of HPO terms was not tweentherequestforfCESandthefinalreportvalidationby
statisticallysignificant,thetrendoftheplotmaysuggestthat a clinical geneticist, was calculated for both cohorts. The
fCES diagnostic yield could be partially determined by an averageTATwas4and2.5monthsfortheretrospectiveand
accurate phenotypic description (Figure 2D). prospective cohorts, respectively. For the latter, TAT
Intheretrospectivecohort,adiagnosiswasreachedin35 improved to 29 working days (range 17-43 working days)
of 120 cases (29%) through multistep analysis (Figure 3A, during the course of our study.
Table2).Thediagnosticratewasthussignificantlyhigherin
the retrospective than in the prospective cohort (N = 303;
X2 = 11.9; P < .001). Most variants (30/35, 86%) were Discussion
(2)
found using the gene panel for congenital anomalies
(Figures 1B and 3A), and the remaining cases required The use of fCES in fetuses presenting with anomalies
analysis of all the fCES genes (5/35, 14%) (Figure 3A). detected using ultrasound allowed the identification of the
Amongthesolvedcases,5werecharacterizedbyapositive underlying genetic cause in 13% prospective and 29%
family history (5/35, 14%). When only consanguineous retrospective cases by using a multistep variant analysis.
couples were considered (n = 15), the diagnostic rate One factor that could explain the difference might be the
increased to 40% (6/15). AD disorders were diagnosed in case recruitment procedure because interrupted pregnancies
49% (17/35) with mostly de novo variants (15/35, 43%) more often displayed a severe multisystem phenotype and
(genes: ACTA1, MYH3, HRAS, PTPN11, DVL1, FLNB, were selected by clinical geneticists. In addition, detailed
RIT1,BRAF,JAG1,KMT2D,COL1A1,GREB1L)(Table2). phenotypic information was available, offering valuable
Parentalmosaicismwasidentified in2ofthecases affected support for variant interpretation. Consequently, the diag-
by AD syndromes (genes: COL1A1, GREB1L) (Table 2). nostic rate of the retrospective cohort was similar to that of
Table2 Overviewofthediagnosesidentifiedintheretrospectivecohort
fCES
Interpretation
Strategythat
Post-mortem Variant Identified
Exams/ Overall Recurrence Variant(s)and Classification the
Case Phenotypic Prenatal Postnatal HPO ofthe Protein Phenotype's Pathogenic Pregnancy
Number Category Phenotype Findings Terms Consanguinity Disorder Gene Transcript Effect(s) Contribution Inheritance Variant(s) Disorder OMIM Outcome
R3 Multiple Bilateral Low-set HP:0001776; N Y NEB NM_ c.13134_ IVFull Compound Insilico Nemaline 256030 TOP
talipes ears,cystic HP:0001188; 001164508.1 13135delAG heterozygote genepanel- myopathy2,
equinovarus, hygroma HP:0000369; p.(Arg4378fs*10) Congenital autosomal
clenched HP:0000476 c.6805C>T anomalies recessive
hands p.(Gln2269*) (design1)
R6 Multiple Bilateral Slightlow-set HP:0001776; N N ACTA1 NM_ c.49G>A VFull Denovo Insilicogenepanel- ACTA1-related 161800/ TOPat24w
talipes ears,pericardial HP:0001561; 001100.4 p.(Gly17Ser) Congenital disorders 255310
equinovarus, effusion, HP:0001789; anomalies
polyhydramnios, pleuraleffusion, HP:0000369; (design1)
hydropsfetalis pulmonary HP:0001698;
hypoplasia, HP:0002202;
increased HP:0002089;
variabilityin HP:0003557
musclefiber
diameter
R14 Multiple Clenched Micropenis, HP:0001188; N N MYH3 NM_ c.2014C>T VFull Denovo Insilico Arthrogryposis, 193700 TOP
hands, slightlow-set HP:0000047; 002470.4 p.(Arg672Cys) genepanel- distal,type
hypospadias ears HP:0000054; Congenital 2A
HP:0000369 anomalies
(design1)
R16 Multiple Hydrops NA HP:0001789; N N HRAS NM_ c.38G>A VFull Denovo Insilicogenepanel- Costello 218040 TOPat24w
fetalis, HP:0001561; 001130442.2 p.(Gly13Asp) Congenital syndrome
polyhydramnios, HP:0010880; anomalies
increased HP:0004719; (design2)
nuchal HP:0003026
translucency,
hyperechogenic
kidneys,
shortlong
bone
R23 Multiple Fetalakinesia NA HP:0001989; N N ASCC1 NM_ c.157dupG VFull Recessive Insilico Spinalmuscular 616867 TOP
sequence, HP:0001776; 001198799.3 p.(Glu53fs*19) homozygote genepanel- atrophywith
bilateraltalipes HP:0001188; Congenital congenitalbone
equinovarus, HP:0001789; anomalies fractures2
clenchedhands, HP:0001561 (design2)
hydropsfetalis,
polyhydramnios
R24 Abnormality Microcephaly, NA HP:0000252; N N ASPM NM_ c.3811C>T V,IVFull Compound Insilico Microcephaly5, 608716 TOP
ofthe cerebellar HP:0001321 018136.5 p.(Arg1271*) heterozygote genepanel- primary, at24w
nervous hypoplasia c.2975C>G Congenital autosomal
system p.(Ser992*) anomalies recessive
(design2)
R27 Multiple Fetal Hypertelorism, HP:0001989; N N GBE1 NM_ c.2081T>A IVFull Compound Insilico Glycogen 232500 TOP
akinesia protruding HP:0001713; 000158.4 p.(Ile694Asn) heterozygote genepanel- storage
sequence, tongue, HP:0005684; c.783C>A Congenital diseaseIV
abnormal longface, HP:0000316; p.(Ser261Arg) anomalies
cardiacventricle pulmonary HP:0010808; (design2)
morphology hypoplasia, HP:0000276;
(asimmetry: abnormallung HP:0002089;
L>R),distal lobation HP:0002101;
arthrogryposis (2onthe HP:0003202;
(clenched Rratherthan3), HP:0000954
hands, skeletalmuscle
hyperflexedlegs, atrophy
bilateraltalipes (muscular
equinovarus) hypotrophy),
single
transverse
palmar
crease
(right)
(continued)
354
M.
Marangoni
et
al.
Table2 Continued
fCES
Interpretation
Strategythat
Post-mortem Variant Identified
Exams/ Overall Recurrence Variant(s)and Classification the
Case Phenotypic Prenatal Postnatal HPO ofthe Protein Phenotype's Pathogenic Pregnancy
Number Category Phenotype Findings Terms Consanguinity Disorder Gene Transcript Effect(s) Contribution Inheritance Variant(s) Disorder OMIM Outcome
R34 Multiple Encephalocele, Hypertelorism, HP:0002084; N N B3GALNT2 NM_ c.261-1G>A IV,VFull Compound Insilico Muscular 615181 TOP
echogenic broadneck HP:0010942; 152490.5 c.824_825dupTT heterozygote genepanel- dystrophy- at17w
intracardiac HP:0000316; p.(Ile276fs*26) Congenital dystroglycanopathy
focus HP:0000475 anomalies (congenital
(design2) withbrainand
eyeanomalies,
typeA,11
R35 Multiple Increasednuchal Hypertelorism, HP:0010880; N N PTPN11 NM_ c.206A>T VFull Denovo Insilicogenepanel- Noonan 163950 Fetal
translucency protruding HP:0000316; 002834.5 p.(Glu69Val) Congenital syndrome1 demise
(7mm) tongue,broad HP:0010808; anomalies at30w
forehead, HP:0000337; (design2)
antevertedears, HP:0040080;
shortneck, HP:0000470;
pesvalgus HP:0008081;
(left),pleural HP:0002202;
effusion, HP:0002089
pulmonary
hypoplasia
R36 Multiple Encephalocele, NA HP:0002084; N N ISPD NM_ c.627_628delAG IVFull Recessive Insilico Muscular 614643/ TOPat
polydactyly HP:0010442 001101426.4 p.(Arg209fs*3) homozygote genepanel- dystrophy- 616052 17w
Congenital dystroglycanopathy
anomalies (congenital
(design2) withbrain
andeye
anomalies),
typeA,7/
Muscular
dystrophy-
dystroglycanopathy
(limb-girdle),
typeC,7
R39 Multiple Oligohydramnios, Hypertelorism, HP:0001562; N N CEP290 NM_ c.5012+5G>T VFull Recessive Insilico Meckel 611134 TOP
ventriculomegaly, microretrognathia, HP:0002119; 025114.4 homozygote genepanel- syndrome4 at23w
occipital hypoplasiaof HP:0002085; Congenital
encephalocele, thethymus, HP:0032269; anomalies
lemon malformationof HP:0001272; (design2)
sign,cerebellar thehepatic HP:0000113;
atrophy, ductalplate HP:0000316;
polycystic HP:0000308;
kidney HP:0000778;
dysplasia, HP:0006563
R41 Abnormality Hydrops NA HP:0001789; N Y PIEZO1 NM_ c.1965C>G IVFull Compound ClinicalExome Lymphatic 616843 TOP
ofthefluid fetalis,edema, HP:0000969; 001142864.4 p.(Tyr655*) heterozygote malformation6 at24w
regulation pleuraleffusion HP:0002202 c.635-1G>A
R46 Abnormality Microcephaly, NA HP:0000252; N N TUBGCP6 NM_ c.1753C>T IVFull Compound Insilico Microcephalyand 251270 TOPat32w
ofthe simplified HP:0009879; 020461.4 p.(Pro585Ser) heterozygote genepanel- chorioretinopathy,
nervous gyralpattern, HP:0002079 c.1115A>G Congenital autosomal
system hypoplasia p.(Gln372Arg) anomalies recessive,1
ofthecorpus (design2)
callosum
R51 Multiple NA Talipes HP:0001762; Y N TNNT3 NM_ c.82+1G>A IVFull Recessive Insilico Arthrogryposis, 618435 Not
equinovarus, HP:0000278; 006757.4 homozygote genepanel- distal,type available
retrognathia, HP:0004426; Congenital 2B2
abnormality HP:0000189; anomalies
ofthecheeks, HP:0010557; (design2)
narrowpalate, HP:0001829;
overlapping HP:0001188;
fingers,polydactyly HP:0000075
(feet),hand
clenching,
renalduplication
(continued)
M.
Marangoni
et
al.
355
Table2 Continued
fCES
Interpretation
Strategythat
Post-mortem Variant Identified
Exams/ Overall Recurrence Variant(s)and Classification the
Case Phenotypic Prenatal Postnatal HPO ofthe Protein Phenotype's Pathogenic Pregnancy
Number Category Phenotype Findings Terms Consanguinity Disorder Gene Transcript Effect(s) Contribution Inheritance Variant(s) Disorder OMIM Outcome
R53 Multiple Bilateral Ulnarbowing, HP:0002744; N N DVL1 NM_ c.1562del VFull Denovo Clinical Robinow 616331 TOPat16w
cleftlip delayed HP:0000280; 004421.3 p.(Pro521Hisfs*128) Exome syndrome,
andpalate, ossification HP:0000316; autosomal
coarsefacial ofthehand HP:0004467; dominant2
features, bones,abnormal HP:0005257;
hypertelorism, footbone HP:0009826;
preauricular ossification, HP:0030084;
pit(bilateral), shortfirst HP:0000054;
thoracic metatarsals, HP:0011304;
hypoplasia, hypoplasic HP:0010055;
limbundergrowth, terminal HP:0009882;
clinodactyly, phalanges HP:0003031;
micropenis, HP:0004052;
broadthumbs, HP:0010675;
broadhallux HP:0010105
R54 Multiple NA Macrocephaly, HP:0000256; N N FLNB NM_ c.512T>C VFull Denovo Insilico FLNB-Related 108720/ TOPat16w
hemifacial HP:0011332; 001164317.2 p.(Leu171Pro) genepanel- Disorders 108721/
hypoplasia, HP:0000520; Congenital 112310/
proptosis, HP:0003196; anomalies 150250
shortnose, HP:0000343; (design2)
longphiltrum, HP:0000175;
cleftpalate, HP:0000369;
low-set HP:0000470;
ears,short HP:0005257;
neck,thoracic HP:0001538;
hypoplasia, HP:0001537;
protuberant HP:0004331;
abdomen, HP:0004599;
umbilicalhernia, HP:0009829;
decreasedskull HP:0004274
ossification,
absentor
minimallyossified
vertebralbodies,
phocomelia,
deficient
ossification
ofhandbones
R62 Multiple Occipital NA HP:0002085; N N IDS NM_ c.818G>A IVFull X-linked Insilico Mucopolysac 309900 TOPat18w
encephalocele, HP:0002436; 000202.8 p.(Arg273Gln) genepanel- -charidosisII
occipital HP:0010945 Congenital
meningocele, anomalies
fetalpyelectasis (design2)
(unilateral)
R66 Multiple Severe Clinodactyly, HP:0008846; N N DDX11 NM_ c.918del IVFull Compound Clinical Warsaw 613398 TOP
intrauterine thinribs, HP:0000520; 001257144.2 p.(Arg307Glyfs*28) heterozygote Exome breakage
growth abnormal HP:0002580; c.1403dup syndrome
retardation bone HP:0001195; p.(Ser469Valfs*32)
(-6wat30w), ossification HP:0100307;
proptosis, (delayed) HP:0030084;
volvulus, HP:0000883;
single HP:0011849
umbilicalartery,
cerebellar
hemisphere
hypoplasia
(continued)
356
M.
Marangoni
et
al.
Table2 Continued
fCES
Interpretation
Strategythat
Post-mortem Variant Identified
Exams/ Overall Recurrence Variant(s)and Classification the
Case Phenotypic Prenatal Postnatal HPO ofthe Protein Phenotype's Pathogenic Pregnancy
Number Category Phenotype Findings Terms Consanguinity Disorder Gene Transcript Effect(s) Contribution Inheritance Variant(s) Disorder OMIM Outcome
R69 Multiple NA Low-setears, HP:0000369; N N RIT1 NM_ c.270G>A VFull Denovo Insilico Noonan 615355 NA
hypertelorism, HP:0000316; 006912.6 p.(Met90Ile) genepanel- syndrome8
thinvermilion HP:0000233; Congenital
border,single HP:0000954; anomalies
transversepalmar HP:0002240; (design2)
crease, HP:0010946;
hepatomegaly, HP:0001713
dilatationof
therenalpelvis,
abnormal
cardiacventricle
morphology
(pronunced
interventricular
groove,dilatation
ofthe
ventricules)
R76 Multiple NA Partialagenesis HP:0001338; Y N HESX1 NM_ c.509C>T IVFull Paternal Insilico Septooptic 182230 TOP
ofthecorpus HP:0002119; 003865.3 p.(Ser170Leu) genepanel- dysplasia
callosum, HP:0002389; Congenital
ventriculomegaly, HP:0011743; anomalies
cavumseptum HP:0011000; (design2)
pellucidum, HP:0012521
adrenalgland
agenesis,
aplasia/
hypoplasia
oftheoptic
tract,optic
nerve
aplasia
R77 Multiple NA Cerebellar HP:0001321; N N BRAF NM_ c.1574T>G IVFull Denovo Insilico BRAF-related 115150/ TOP
hypoplasia, HP:0000347; 004333.6 p.(Leu525Arg) genepanel- disorders 613707/
micrognathia, HP:0000316; Congenital 613706
hypertelorism, HP:0001591; anomalies
bellshaped HP:0030084; (design2)
chest, HP:0002101
clinodactyly,
abnormal
lunglobation
R84 Abnormality Ventricular NA HP:0001629; N N JAG1 NM_ c.1720+2T>C VFull Denovo Insilico Alagille 118450 TOPat24w
ofthe septaldefect, HP:0004415 000214.3 genepanel- syndrome1
cardiovascular Pulmonary Congenital
system arterystenosis anomalies
(design2)
(continued)
M.
Marangoni
et
al.
357
Table2 Continued
fCES
Interpretation
Strategythat
Post-mortem Variant Identified
Exams/ Overall Recurrence Variant(s)and Classification the
Case Phenotypic Prenatal Postnatal HPO ofthe Protein Phenotype's Pathogenic Pregnancy
Number Category Phenotype Findings Terms Consanguinity Disorder Gene Transcript Effect(s) Contribution Inheritance Variant(s) Disorder OMIM Outcome
R90 Multiple Polyhydramnios, Brachycephaly, HP:0001561; Y N ALG3 NM_ c.667_ IVFull Recessive Clinical Congenital 601110 TOP
decreased thickenedears, HP:0001558; 005787.6 669delCTC homozygote Exome disorderof at34w
fetalmovement, abnormally HP:0003026; p.(Leu223del) glycosylation,
shortlong foldedhelix, HP:0000308; typeId
bone, pulmonary HP:0001188;
microretrognathia, hypoplasia, HP:0001321;
handclenching, dextrocardia, HP:0001761;
cerebellar longitudinal HP:0001845;
hypoplasia, vaginal HP:0010955;
pescavus, septum HP:0000252;
overlappingtoe, HP:0001320;
dilatationof HP:0002126;
thebladder, HP:0040010;
microcephaly, HP:0012704;
cerebellar HP:0000776;
vermis HP:0003396;
hypoplasia, HP:0000248;
polymicrogyria, HP:0009894;
smallposterior HP:0008544;
fossa,widened HP:0002089;
subarachnoid HP:0001651;
space,congenital HP:0008740
diaphragmatic
hernia,
syringomyelia
R97 Multiple Fetal NA HP:0001989; Y Y ASCC1 NM_ c.157dupG VFull Recessive Insilico Spinal 616867 Fetal
akinesia HP:0001791; 001198799.3 p.(Glu53Glyfs*19) homozygote genepanel- muscular demisein
sequence, HP:0012050 Congenital atrophywith utero
fetalascites, anomalies congenital at32w
anasarca (design2) bone
fractures2
R100 Multiple Talipes, Atrialseptal HP:0001883; N N KMT2D NM_ c.10180C>T IVFull Denovo Insilico Kabuki 147920 Fetaldemise
polyhydramnios, defect,cleft HP:0001561; 003482.4 p.(Gln3394*) genepanel- syndrome1 inutero
shortphiltrum, palate, HP:0000322; Congenital 37w
Rkidney horseshoe HP:0001631; anomalies
not kidney(L), HP:0000175; (design2)
visualised pelvickidney(R), HP:0000085;
graymatter HP:0000125;
heterotopia HP:0002282
R108 Abnormality Dolichocephaly, NA HP:0000268; N N COL1A1 NM_ c.1777G>A VFull Denovo Insilico Osteogenesis 259420/ Fetal
oftheskeletal abnormal HP:0002696; 000088.4 p.(Gly593Ser) (maternal genepanel- imperfecta, 166220 demisein
system parietal HP:0003026; mosaicism) Congenital typeIII/ uteroat
bone HP:0000773; anomalies typeIV 21w
morphology, HP:0001591; (design3)
shortlong HP:0002652;
bones, HP:0006487
shortribs,
bell-shaped
thorax,
skeletaldysplasia,
bowing
ofthe
long
bones
(continued)
358
M.
Marangoni
et
al.
Table2 Continued
fCES
Interpretation
Strategythat
Post-mortem Variant Identified
Exams/ Overall Recurrence Variant(s)and Classification the
Case Phenotypic Prenatal Postnatal HPO ofthe Protein Phenotype's Pathogenic Pregnancy
Number Category Phenotype Findings Terms Consanguinity Disorder Gene Transcript Effect(s) Contribution Inheritance Variant(s) Disorder OMIM Outcome
R109 Multiple N Partial HP:0002951; N N ETFA NM_ c.251dupA IV,VFull Compound Insilico Glutaric 231680 Newborn
absenceof HP:0002269; 000126.4 p.(Tyr84*) heterozygote genepanel- acidemia dead
cerebellar HP:0001302; c.494T>C Congenital IIA after2d
vermis, HP:0001680; p.(Val165Ala) anomalies
abnormalityof HP:0001397; (design3)
neuronal HP:0011769;
migration, HP:0010517;
pachygyria, HP:0000034
coarctationof
aorta,hepatic
steatosis,
ectopic
parathyroid,
ectopicthymus
tissue,
hydrocele
testis
R111 Abnormality Bilateral NA HP:0010958 N N GREB1L NM_ c.5074G>T IVFull Denovo Insilico Renal 617805 Not
ofthe renal 001142966.2 p.(Asp1692Tyr) (paternal genepanel- hypodysplasia/ available
urinary agenesis mosaicism) Congenital aplasia3
system anomalies
(design3)
R116 Abnormality Ventriculomegaly, NA HP:0002119; N N PDHA1 NM_ c.1035_ IVFull Denovo, Insilico Pyruvate 312170 Newborn,
ofthe cerebellar HP:0001321; 001173454.1 1050dupTCA XLD genepanel- dehydrogenase neonatal
nervous hypoplasia, HP:0002120 GGAAGTA Congenital E1-alpha death
system cerebral AGAAGT anomalies deficiency
corticalatrophy p.(Lys351 (design3)
SerfsTer8)
R118 Multiple Intrauterine Secundum HP:0001511; N Y ANKRD11 NM_ c.2408_ VFull Maternal Insilico KBG 148050 Fetal
growth atrial HP:0002190; 001256183.2 2412delAAAAA genepanel- syndrome demise
retardation, septaldefect, HP:0001195; p.(Lys803Argfs*5) Congenital at25w
choroid ventricular HP:0001684; anomalies
plexuscyst, septaldefect, HP:0001629; (design3)
singleumbilical hepaticnecrosis, HP:0002605;
artery,suspicion enlargedkidneys, HP:0000105;
ofcongenital adrenalhypoplasia, HP:0000835;
heartdefects graymatter HP:0002282;
heterotopia, HP:0000952;
jaundice,edema HP:0000969
Detailsareprovidedonlywhenthepatientsagreedwithpersonaldatapublication(30/35).
M.
Marangoni
et
al.
359
360 M. Marangoni et al.
the postnatal series.10,15 Conversely, the prospective cohort adaptedvariantselectioncriteriaalsoincreasedthediagnostic
included unselected cases, notably some with fetal anoma- yield (8.3% in the prospective cohort) (Figure 2A).
lies weakly associated with monogenic findings (ie, In addition to expanding our understanding of fetal pre-
increased NT or neural tube defects). Furthermore, variant sentations for known genetic conditions (as in case P6,
interpretationwashamperedbythelimitedknowledgeofin described in28) and identifying new types of pathogenic
utero phenotypes. Results from the unselected cohort are variants in association with them (as in case P32, reported
comparablewiththeonesdescribedinotherESprospective in29), phenotypes resembling conditions not previously re-
studies in which diagnostic variants were detected in 8.5% portedprenatallymaybeidentified,leadingtochallengesin
to 10.3% of cases.16,17 Our slightly higher diagnostic yield data interpretation and assessment of the variants’ patho-
maybeexplainedbyagreaterproportionofconsanguineous genicity (represented here by case P131). Additional chal-
couples (12/171, 7%). lenges arise with recessive pathologies for which only 1
The highest diagnostic rates were achieved for fetuses pathogenic variant is detected, such as in prospective case
presenting with multisystem and cerebral anomalies in the P136.Finally,furtheranalysisofspecificgenepanelsusing
retrospective cohort. In the multisystem subgroup, a simplex analysis allowed the detection of inherited patho-
conclusive molecular diagnosis was reached for most cases genicvariantsresponsibleforADdisorderswithincomplete
with a fetal akinesia sequence (9/11, 82%) or a Meckel- penetrance orthediscovery of1diagnosticvariantingenes
Gruber–related phenotype (5/6, 83%), indicating that fCES responsible for AR disorders consistent with the fetal
ishighlyrecommendedfortheseultrasoundfindings.Inthe phenotype,whichwouldotherwisehavebeenmissedifonly
prospective cohort, diagnostic rates were highest in fetuses trio-based analysis was performed (P136).
with multiple systems, skeletal, urinary, and cerebral In most of the reported VUS, the variants were heterozy-
anomalies. These results are in agreement with previous gous in an asymptomatic parent, and further clinical exami-
studies,16,17 although higher rates for fetuses with cardiac16 nationsandsegregationanalysiswererecommendedtoassess
andlymphatic17anomalieswerealsodescribed.Becausethe pathogenicity.Incompletepenetranceandvariableexpression
proportionofcasesbelongingtothesephenotypiccategories among family members (eg, variants within the COL4A2
wassmallinourcohort,furtherstudiesarerequiredtodraw gene and risk of porencephaly) complicate evaluation, and
final conclusions. Similarly, the absence of diagnostic var- these variants often remain of unknown significance until
iants in rarely explored phenotypic categories (ie, isolated similar cases with the same variant are identified in inde-
intrauterinegrowthrestrictionandanomaliesoftheamniotic pendent families. VUS may also contribute to some pheno-
fluid)needstobefurtherinvestigatedinlargerseries.Inline typic features that a diagnostic variant could not explain (as
with other studies, no NGS diagnostic variants were found found in case P158) (Table 1). Although smaller, focused
in fetuses with either neural tube defects or isolated gene panels limit the incidental identification of VUS16 and
increased NT.16,23 More data, more exploratory variant se- truediagnosesmayalsobemissed,25makingtheselectionof
lection, and more complex heritability investigations (eg, the most appropriate analysis method challenging.
oligogenic, noncoding, polygenic) will be necessary to As fCES/ES become more widely implemented, it is
assess the diagnostic yield of NGS in these anomalies. crucial to share phenotypic and molecular data in interna-
Interestingly, our study shows that the proportion of AD tional databases to improve variant interpretation and
and AR diagnoses was the same, which is in contrast with recognition ofnovel fetal genotype–phenotypecorrelations.
reports related to postnatal series in which de novo variants Theabsenceofastatisticallysignificantcorrelationbetween
accounted for most of the cases.24 Remarkably, our study the number of HPO terms and the percentage of conclusive
shows the importance of investigating compound heterozy- diagnosesmaybeexplainedbymultiplefactors,suchasthe
gousvariants(especiallyinnonconsanguineouscases)because reduced number of cases presenting with a high number of
they represent 54.5% and 26% of positive AR diagnoses in HPO terms, the presence of cases with multiple anomalies
our2cohorts.ThisresultmaybeexplainedbythefactthatAR with a low-level association with monogenic diseases, and/
diseases are more often responsible for the interruption of or the fact that some genetic anomalies or variants in genes
pregnancy or perinatal lethality. Other fetal series observed not studied in our design are not detected. Further analyses
similarproportions,12,16,17,25suggestingthatARdisordersplay onlargerseries willbeneeded todrawfinalconclusionson
an important role in severe fetal phenotypes. theimportanceoftheHPOterminologyusage.Nonetheless,
On the basis of the experience accumulated in this and we highly recommend that clinicians requesting fetal NGS
otherstudies,11,26,27itseemsbeneficialtoperformatrio/duo- provide detailed clinical information and family history to
basedanalysisinvolving all the genes ofthe clinicalexome. genetics laboratories.18 Moreover, in the context of inter-
Such an analysis strategy carries a diagnostic gain of 16.7% rupted pregnancies, the complementary information identi-
(prospective cases) and 14% (retrospective cohort) when fied by postmortem examination strongly contributes to a
compared with a trio/duo analysis focused on a comprehen- higherdiagnosticyield.Ofnote,weencountereddifficulties
sive congenital anomalies gene panel designed using litera- in describing some fetal phenotypes because HPO terms
ture(Figures2Aand3A).Incomplementtothisstrategy,we were missing for a portion of prenatal anomalies detected
found that, when appropriate, a simplex analysis of in silico using ultrasound (eg, antenatal hyperechoic colon) or sub-
panelscomprisinggenesspecificforthefetalphenotypewith types of anomalies. We thus believe that efforts should be
M. Marangoni et al. 361
made to expand the existing fetal HPO terminology. Simi- shared). Further details about our methods are available
larly, we found that variant classification could be particu- upon request.
larly challenging in a prenatal setting because classical
criteria21 were not always applicable given the inevitably
Acknowledgments
limited phenotypic characterization in utero.
Ourstudyhaslimitationsregardingthediagnosisofsome
phenotypic categories that will require further clinical The authors thank the parents and the referring physicians
evaluations. Another limitation of our study is that exonic who contributed to this study. The authors acknowledge all
the members of the Molecular Genetics Laboratory of the
CNVs were not routinely investigated and were only
Hoˆpital Erasme for their valuable technical assistance. The
analyzed when 1 diagnostic variant was already found in a
authors thank the FNRS which supported M.M. through a
genecausinganARphenotype.Incontrasttootherstudies,
FRIA-FNRS fellowship.
ES was not performed. Although our approach limits the
discovery of new disease-causing genes and the data rean-
alysis power, it is suitable for a prenatal clinical setting,
Author Information
allowing very high-quality coverage data in well-known
genes causing Mendelian disorders with prenatal onset. In
Conceptualization: M.M., G.S., J.D., M.A., I.M.; Data
addition, clinical exome sequencing (CES)/ES-based
Curation: M.M.; Formal Analysis: M.M.; Investigation:
methods are limited to the detection of coding variants and
M.M.; Methodology: M.M., G.S., C.V.; Resources: G.S.,
misses some genetic defects (eg, deep intronic variants,
G.C., E.C., R.C., C.D., C.D.C., S.D., K.G., G.G., C.G.,
nucleotide repeat expansions). This limitation can be over-
M.G., A.H., C.H., J.M., C.N., C.R., S.R., J.S., A.S.-T.,
comebygenomesequencing(GS).However,becauseofthe
greater cost of GS over CES/ES-based methods, it is likely M.V.R., A.V., S.Z., S.B., N.D'H., D.D'O., C.D., M.L.R.,
that combined CMA and CES/ES-based analysis will L.R., V.S., C.V., E.F.A., M.C., A.M., B.B., E.B.-B., S.B.,
become more widely implemented before the advent of GS T.D.R., G.D., B.D., S.J., K.K., M.L., K.v.B., L.V.M., I.V.,
in the prenatal clinical setting. The refined prenatal C.V., C.D., L.T., D.T., M.A., J.D., I.M.; Supervision: G.S.,
phenotype–genotype correlations expected to be obtained J.D., M.A., I.M.; Visualization: M.M.; Writing-original
draft: M.M.; Writing-review & editing: G.S., M.A., I.M.
from CES/ES-based methods will likely facilitate the sub-
sequent implementation of fetal GS.
In conclusion, this study showed that the overall diag-
nosticyieldsofCESusingamultistepvariantanalysiswere Ethics Declaration
13% and 29% in prospective and retrospective cases,
respectively.Inparticular,trio/duo-basedanalysisinvolving This study was approved by the ethical committee of the
allthegenesoftheclinicalexomeandsimplexanalysis(ie, Hoˆpital Erasme, Brussels, Belgium, under the reference
in silico panels on fCES data comprising genes specific for P2016/236. Informed consent was obtained from all par-
the fetal phenotype) were complementary to achieve the ticipants. This study adheres to the principles set out in the
highest diagnostic rate possible, and compound heterozy- Declaration of Helsinki.
gous genotypes were not rare. fCES-based diagnosis was
efficient in fetuses presenting with cerebral, skeletal, uri-
nary, or multiple anomalies. The comparison between a Conflict of Interest
retrospective and a prospective cohort highlighted the
importance of providing detailed phenotypic information to The authors declare no conflict of interest.
genetic laboratories performing fetal NGS for better inter-
pretation and reporting of genetic variants. Finally,selected
cases illustrate some interpretation challenges faced during
Additional Information
theanalysisofgenome-widedataandwidentheknowledge
of the prenatal presentation of genetic syndromes.
The online version of this article (https://doi.org/10.1016/j.
gim.2021.09.016) contains supplementary material, which
Data Availability is available to authorized users.
Clinical and genetic data of 198 of 303 patients are
describedindetailinSupplementalTables6and7).Forthe Authors
remaining 105 of 303 cases for whom no formal informed
consent for the sharing of personal data was provided, only MartinaMarangoni1,* ,GuillaumeSmits1,GillesCeysens2,3,
limitedinformationwasincludedinthegeneralstatistics(ie, Elena Costa4, Robert Coulon5, Caroline Daelemans4,
onlytheirphenotypiccategoriesandthepresence/absenceof CarolineDeConinck4,SaraDerisbourg4,KalinaGajewska6,
diagnostic variant(s)/variants of uncertain significance were Giulia Garofalo7, Caroline Gounongbe7, Meriem Guizani7,
362 M. Marangoni et al.
Anne Holoye4, Catherine Houba7, Jean Makhoul8, Genetics, University Hospital Ghent, Ghent, Belgium;
Christian Norgaard9, Cecile Regnard4, Stephanie Rome´e4, 23DepartmentofGenetics,HoˆpitalUniversitairedesEnfants
Jamil Soto8, Aurore Stagel-Trabbia8, Reine Fabiola, Brussels, Belgium; 24Center for Medical
Michel Van Rysselberge7, An Vercoutere4, Genetics, Institut de Pathologie et de Ge´ne´tique Gosselies,
Siham Zaytouni4, Sarah Bouri10, Nicky D'Haene10, Charleroi, Belgium; 25Departmentof Genetic Medicine and
Dominique D'Onle11, Christian Dugauquier12, Development, Faculty of Medicine, University of Geneva,
Marie-Lucie Racu10, Laureen Rocq10, Vale´rie Segers13, Geneva, Switzerland; 26Fonds de la Recherche Scientifique
Camille Verocq10, Ephraim Freddy Avni14, (FNRS), Brussels, Belgium
Marie Cassart15,16, Anne Massez17, Bettina Blaumeiser18,
Elise Brischoux-Boucher19, Saskia Bulk20,
Thomy De Ravel21, Guillaume Debray20, References
Boyan Dimitrov21, Sandra Janssens22,
Kathelijn Keymolen21, Marie Laterre20, Kim van Berkel21,
1. Calzolari E, Barisic I, Loane M, et al. Epidemiology of multiple
Lionel Van Maldergem19, Isabelle Vandernoot1,
congenitalanomaliesinEurope:aEUROCATpopulation-basedregistry
Catheline Vilain1,23, Catherine Donner4, Laura Tecco7, study. Birth Defects Res A Clin Mol Teratol. 2014;100(4):270–276.
DominiqueThomas8,JulieDe´sir1,24,MarcAbramowicz1,25, http://doi.org/10.1002/bdra.23240.
Isabelle Migeotte1,26,* 2. KarimJN,RobertsNW,SalomonLJ,PapageorghiouAT.Systematic
review of first-trimester ultrasound screening for detection of fetal
structural anomalies and factors that affect screening performance.
Ultrasound Obstet Gynecol. 2017;50(4):429–441. http://doi.org/10.
Affiliations
1002/uog.17246.
3. WapnerRJ,MartinCL,LevyB,etal.Chromosomalmicroarrayversus
karyotyping for prenatal diagnosis. N Engl J Med. 2012;367(23):
1Center of Human Genetics, Hoˆpital Erasme, Universite´ 2175–2184.http://doi.org/10.1056/NEJMoa1203382.
Libre de Bruxelles, Brussels, Belgium; 2Department of 4. CallawayJLA,ShafferLG,ChittyLS,RosenfeldJA,CrollaJA.The
Obstetrics and Gynecology, Hoˆpital Erasme, Universite´ clinical utility of microarray technologies applied to prenatal cytoge-
Libre de Bruxelles, Brussels, Belgium; 3Department of neticsinthepresenceofanormalconventionalkaryotype:areviewof
Obstetrics and Gynecology, Hoˆpital Ambroise Pare´, Mons,
theliterature.PrenatDiagn.2013;33(12):1119–1123.http://doi.org/10.
1002/pd.4209.
Belgium; 4Department of Obstetrics and Gynecology,
5. HillmanSC,McMullanDJ,HallG,etal.Useofprenatalchromosomal
Hoˆpital Erasme, Universite´ Libre de Bruxelles, Brussels, microarray:prospectivecohortstudyandsystematicreviewandmeta-
Belgium; 5Department of Obstetrics and Gynecology, analysis. Ultrasound Obstet Gynecol. 2013;41(6):610–620. http://doi.
Centre Hospitalier EpiCURA, Ath, Belgium; 6Department org/10.1002/uog.12464.
of Obstetrics and Gynecology, Hoˆpital Civil Marie Curie, 6. DecipheringDevelopmentalDisordersStudy.Large-scalediscoveryof
novel genetic causes of developmental disorders. Nature. 2015;519
Charleroi, Belgium; 7Department of Fetal Medicine, CHU (7542):223–228.http://doi.org/10.1038/nature14135.
Saint-Pierre, Brussels, Belgium; 8Department of Gynecol- 7. Lee H, DeignanJL, DorraniN, et al. Clinical exome sequencingfor
ogy and Obstetrics, Hoˆpitaux Iris Sud–Etterbeek-Ixelles, genetic identification of rare Mendelian disorders. JAMA. 2014;312
Brussels, Belgium; 9Department of Obstetrics and Gyne- (18):1880–1887.http://doi.org/10.1001/jama.2014.14604.
cology, CHIREC - Braine-l'Alleud-Waterloo Hospital, 8. Retterer K, Juusola J, Cho MT, et al. Clinical application of whole-
exome sequencing across clinical indications. Genet Med. 2016;18
Braine l'Alleud, Belgium; 10Department of Pathology, (7):696–704.http://doi.org/10.1038/gim.2015.148.
Hoˆpital Erasme, Universite´ Libre de Bruxelles, Brussels, 9. YangY,MuznyDM,ReidJG,etal.Clinicalwhole-exomesequencing
Belgium;11DepartmentofAnatomopathology,InstitutJules forthediagnosisofMendeliandisorders.NEnglJMed.2013;369(16):
Bordet, Brussels, Belgium; 12Department of Pathology, 1502–1511.http://doi.org/10.1056/NEJMoa1306555.
Institut de Pathologie et de Ge´ne´tique Gosselies, Charleroi, 10. Zhu X, Petrovski S, Xie P, et al. Whole-exome sequencing in undi-
agnosedgeneticdiseases:interpreting119trios.GenetMed.2015;17
Belgium; 13Department of Anatomopathology, CHU Brug- (10):774–781.http://doi.org/10.1038/gim.2014.191.
mann, Brussels, Belgium; 14Department of Radiology, 11. DruryS,WilliamsH,TrumpN,etal.Exomesequencingforprenatal
Hoˆpital Delta, Brussels, Belgium; 15Department of Fetal diagnosis of fetuses with sonographic abnormalities. Prenat Diagn.
Medicine, CHU Saint-Pierre, Brussels, Belgium; 16Depart-
2015;35(10):1010–1017.http://doi.org/10.1002/pd.4675.
12. NormandEA,BraxtonA,NassefS,etal.Clinicalexomesequencing
ment of Perinatal Imaging Radiology, Etterbeek-Ixelles
for fetuses with ultrasound abnormalities and a suspected Mendelian
Hospital, Brussels, Belgium; 17Department of Radiology, disorder.GenomeMed.2018;10(1):74.http://doi.org/10.1186/s13073-
Hoˆpital Erasme, Universite´ Libre de Bruxelles, Brussels, 018-0582-x.
Belgium; 18Center for Medical Genetics, Universiteit en 13. PangalosC,HagnefeltB,LilakosK,KonialisC.Firstapplicationsofa
targeted exome sequencing approach in fetuses with ultrasound ab-
Universitair Ziekenhuis Antwerpen, Antwerp, Belgium;
normalitiesrevealsanimportantfractionofcaseswithassociatedgene
19CenterofHumanGenetics,Universite´ deFranche-Comte´,
defects.PeerJ.2016;4:e1955.http://doi.org/10.7717/peerj.1955.
Besanc¸on, France; 20Center of Human Genetics, CHU de 14. Vora NL, Powell B, Brandt A, et al. Prenatal exome sequencing in
Lie`ge, Lie`ge, Belgium; 21Centre for Medical Genetics, anomalous fetuses: new opportunities and challenges. Genet Med.
2017;19(11):1207–1216.http://doi.org/10.1038/gim.2017.33.
Reproduction and Genetics, Reproduction Genetics and
15. YangY,MuznyDM,XiaF,etal.Molecularfindingsamongpatients
Regenerative Medicine, Vrije Universiteit Brussel (VUB),
referred for clinical whole-exome sequencing. JAMA. 2014;312(18):
UZ Brussel, Brussels, Belgium; 22Center for Medical 1870–1879.http://doi.org/10.1001/jama.2014.14601.
M. Marangoni et al. 363
16. LordJ,McMullanDJ,EberhardtRY,etal.Prenatalexomesequencing 23. DaumH,MeinerV,ElpelegO,HarelT,CollaboratingAuthors.Fetal
analysis in fetal structural anomalies detected by ultrasonography exome sequencing: yield and limitations in a tertiary referral center.
(PAGE):acohortstudy.Lancet.2019;393(10173):747–757.http://doi. UltrasoundObstetGynecol.2019;53(1):80–86.http://doi.org/10.1002/
org/10.1016/S0140-6736(18)31940-8. uog.19168.
17. PetrovskiS,AggarwalV,GiordanoJL,etal.Whole-exomesequencing 24. WrightCF,McRaeJF,ClaytonS,etal.Makingnewgeneticdiagnoses
in the evaluation of fetal structural anomalies: a prospective cohort witholddata:iterativereanalysisandreportingfromgenome-widedata
study. Lancet. 2019;393(10173):758–767. http://doi.org/10.1016/ in 1,133 families with developmental disorders. Genet Med.
S0140-6736(18)32042-7. 2018;20(10):1216–1223.http://doi.org/10.1038/gim.2017.246.
18. Monaghan KG, Leach NT, Pekarek D, Prasad P, Rose NC. ACMG 25. de Koning MA, Haak MC, Adama van Scheltema PN, et al. From
ProfessionalPracticeandGuidelinesCommittee.Theuseoffetalexome diagnostic yield to clinical impact: a pilot study on the imple-
sequencinginprenataldiagnosis:apointstoconsiderdocumentofthe mentation of prenatal exome sequencing in routine care. Genet
AmericanCollegeofMedicalGeneticsandGenomics(ACMG).Genet Med. 2019;21(10):2303–2310. http://doi.org/10.1038/s41436-019-
Med.2020;22(4):675–680.http://doi.org/10.1038/s41436-019-0731-7. 0499-9.
19. Ko¨hlerS,VasilevskyNA,EngelstadM,etal.Thehumanphenotype 26. BecherN,AndreasenL,SandagerP,etal.Implementationofexome
ontologyin2017.NucleicAcidsRes.2017;45(D1):D865–D876.http:// sequencing in fetal diagnostics-Data and experiences from a tertiary
doi.org/10.1093/nar/gkw1039. centerinDenmark.ActaObstetGynecolScand.2020;99(6):783–790.
20. Johansson LF, van Dijk F, de Boer EN, et al. CoNVaDING: single http://doi.org/10.1111/aogs.13871.
exon variation detection in targeted NGS data. Hum Mutat. 27. Sukenik-HalevyR,Ruhrman-ShaharN,OrensteinN,etal.Thediag-
2016;37(5):457–464.http://doi.org/10.1002/humu.22969. nosticefficacyofexomedataanalysisusingfixedneurodevelopmental
21. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the gene lists: implications for prenatal setting. Prenat Diagn.
interpretationofsequencevariants:ajointconsensusrecommendationof 2021;41(6):701–707.http://doi.org/10.1002/pd.5929.
theAmericanCollegeofMedicalGeneticsandGenomicsandtheAs- 28. De Graer C, Marangoni M, Romne´e S, et al. Novel features of
sociation for Molecular Pathology. Genet Med. 2015;17(5):405–424. PIK3CA-Related Overgrowth Spectrum: lesson from an aborted
http://doi.org/10.1038/gim.2015.30. fetus presenting a de novo constitutional PIK3CA mutation. Eur J
22. KaliaSS,AdelmanK,BaleSJ,etal.Recommendationsforreportingof MedGenet.2020;63(4):103775.http://doi.org/10.1016/j.ejmg.2019.
secondary findings in clinical exome and genome sequencing, 2016 103775.
update(ACMGSFv2.0):apolicystatementoftheAmericanCollege 29. Gounongbe´ C,MarangoniM,GouderdeBeauregardV,etal.Middle
ofMedicalGeneticsandGenomics.GenetMed.2017;19(2):249–255. interhemisphericvariantofholoprosencephaly:firstprenatalreportofa
Published correction appears in Genet Med. 2017;19(4):484. https:// ZIC2missensemutation.ClinCaseRep.2020;8(7):1287–1292.http://
doi.org/10.1038/gim.2016.190. doi.org/10.1002/ccr3.2896.
